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Abstract
There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in
the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D
dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical
firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we
observe a decline of the total number of publications by large firms. Second, we show a relative increase of their
external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular
towards computation, health services and more clinical approaches.  Also evident is a more pronounced decline in
publications by both R&D laboratories located in Europe and by firms with European headquarters.  Finally, while
publications by big pharma in emerging economies sharply increase, they remain extremely low compared with those in
developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research
efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical
firms are increasingly becoming ?networks integrators? rather than the prime locus of drug discovery. 
Jelcodes:L23,O32
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Abstract 
 
There is a widespread perception that pharmaceutical R&D is facing a productivity crisis 
characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D 
costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all 
R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. 
The empirical findings present an industry in transformation. In the first place, we observe a decline 
of the total number of publications by large firms. Second, we show a relative increase of their 
external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary 
base, in particular towards computation, health services and more clinical approaches.  Also evident 
is a more pronounced decline in publications by both R&D laboratories located in Europe and by 
firms with European headquarters.  Finally, while publications by big pharma in emerging economies 
sharply increase, they remain extremely low compared with those in developed countries. In 
summary, the trend in this transformation is one of a gradual decrease in internal research efforts 
and increasing reliance on external research. These empirical insights support the view that large 
pharmaceutical firms are increasingly becoming ͚ŶĞƚǁŽƌŬƐ ŝŶƚĞŐƌĂƚŽƌƐ͛ rather than the prime locus 
of drug discovery.  
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1. Introduction 
 
Studies from a variety of sources and perspectives suggest that the pharmaceutical industry is facing 
a productivity crisis and is undergoing a substantial transformation. A stagnant or declining number 
of new chemical entities (NCE) are approved each year in spite of major increases of R&D 
expenditures (Munos 2009; Pammolli, Magazzini, and Riccaboni 2011). As a response the 
pharmaceutical industry has engaged in a series of major mergers and waves of acquisitions, closed 
R&D sites, particularly in Europe and the US, sought cost savings through rationalisation (LaMattina 
2011) and opened R&D laboratories in emerging countries with large markets such as India and 
China (Anon. 2010). The industry is increasingly outsourcing R&D to external research organisations, 
which is perceived to improve efficiency (Baum 2010). Governments are supporting these trends by 
increasingly focusing public sector funding on ͚ƚƌĂŶƐůĂƚŝŽŶĂů͛ ƌĞƐĞĂƌĐŚ (Collins 2011). 
 
In this paper we explore these shifts by studying changes in the publication activities of ƚŚĞ ǁŽƌůĚ͛Ɛ 
15 largest pharmaceutical firms in Europe and the US ;͚ďŝŐ ƉŚĂƌŵĂ͛Ϳ. Historically, the role of big 
pharma in the production of scientific research has been important, with a collective R&D 
investment of $46bn on average over 2004-2007 (see Table 1) compared to an average annual spend 
of $28.5bn by the US National Institute of Health (NIH) over the same period.1 As a result, the 
publication activity of the pharmaceutical firms is large (~10,000 document/year) and may be 
explored to trace changes in the industry.  Publication data does not provide direct insight into the 
R&D processes because a variety of factors shape and mediate propensity to publish, but as 
discussed in the next section when handled with care and contrasted with other data sources, 
publication rate and patterns may shed some light on dynamics in the quantity, areas and modalities 
of R&D efforts, and thus provide glimpses of the underlying processes of change (Tijssen 2004, 713ʹ
715). 
 
We will explore the shift in the industry from three perspectives: How has the knowledge base of 
pharma changed? How has its organisational structure evolved? How have pharmaceutical firms 
relocated their R&D activities? First, in the cognitive sphere, the shift since the 1970-80s with the 
advent of biotechnology from a random-screening regime, towards a guided-search regime could be 
expected to make pharma R&D more reliant on basic biological research (McKelvey, Orsenigo, and 
Pammolli 2004; Hopkins et al. 2007). However, the cumulative nature of competence acquisition by 
firms, means that this process would be expected to occur in a progressive manner (Nightingale and 
Martin 2004; Hopkins et al. 2007), rather than a disruptive one (Hwang and Christensen 2008). What 
do publications data tell us about the changes in the knowledge base? 
 
Second, at the organisational level, the interaction between biotechnology firms and pharmaceutical 
industry has been presented as ƚŚĞ ƉƌŽƚŽƚǇƉŝĐĂů ĞǆĂŵƉůĞ ŽĨ ƚŚĞ ŽƌŐĂŶŝƐĂƚŝŽŶĂů ŶĞƚǁŽƌŬ ĂƐ ƚŚĞ ͚ůŽĐƵƐ 
ŽĨ ŝŶŶŽǀĂƚŝŽŶ͛ (Powell, Koput, and Smith-Doerr 1996), with an estimate of 25% of R&D being 
outsourced in the UK (Howells, Gagliardi, and Malik 2008). Recent empirical research has also shown 
evidence for this shift in terms of drug discovery. (Munos 2009, 965) showed that the share of the 
drugs approved by large firms in the US has steadily decreased from ~80% in 1980 to about ~50% in 
2008. Kneller (2010) reported that at least half the new drugs discovered in the USA between 1998 
and 2007 originated from public laboratories or small firms (see also (Angell 2004, 52ʹ73)).2 If this is 
the case, can we see an increase in the dependence of big pharma on external collaborations? Is 
ƚŚĞƌĞ ĞǀŝĚĞŶĐĞ ŽĨ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ‘ΘD ďĞĐŽŵŝŶŐ ůĞƐƐ ͚‘͛ ;ƌĞƐĞĂƌĐŚͿ ĂŶĚ ŵŽƌĞ ͚D͛ (development)?  
 
                                                          
1
 See NIH budget at http://www.nih.gov/about/director/budgetrequest/  
2
 In the case of biotechnology-related patents the growth of small firms is even faster: from less than 15% in 
1990-94 to more than 35% in 2000-04, with big pharma shrinking from ~42% to ~31% (Parimal Patel, Arundel, 
and Hopkins 2008). 
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Third, from a geographical perspective, the internationalisation of R&D either by off-shoring internal 
R&D or outsourcing it using external collaborations, has received significant policy and media 
attention. The perceived relocation of pharmaceutical activities is often accompanied by stories of 
European weakness in comparison to the US  (Tijssen 2009). Given the relative importance of the 
pharmaceutical industry in various European economies, and its position as one of the (few) high-
tech industries with a dominant European base, the potential decline of this sector has been a 
regular concern in the EU (e.g. see (Tijssen 2009; Pammolli, Magazzini, and Riccaboni 2011)). Do 
publications support the view of a European decline?  Given the observation that interactions 
ďĞƚǁĞĞŶ ƉƵďůŝĐůǇ ĨƵŶĚĞĚ ƌĞƐĞĂƌĐŚ ĂŶĚ ĨŝƌŵƐ͛ ‘ΘD ĞĨĨŽƌƚƐ ŽĨƚĞŶ ƚĂŬĞ ƉůĂĐĞ ŝŶ ĐůŽƐĞ ŐĞŽŐƌĂƉŚŝĐĂů 
proximity is this European decline also visible in big ƉŚĂƌŵĂ͛Ɛ ĐŽůůĂďŽƌĂƚive links?  
 
Table 1. List of largest European and USA pharmaceutical firms mapped in this study. 
 
Company Publications 
1995-2009 
Employees (2008) R&D spent/year 
(2004-2007 in M £) 
GlaxoSmithKline  19,331 101,133 3,186 
Novartis 15,477 96,717 3,604 
HoffmannʹLa Roche 14,351 80,080 4,195 
AstraZeneca  11,378 66,100 2,740 
Sanofi-Aventis  11,211 98,213 3,722 
Bayer 8,125 107,299 2,270 
Novo Nordisk  3,378 31,062 837 
Boehringer Ingelheim  3,036 41,300 1,425 
Aggregate EU  84,863 621,904 21,979 
        
Pfizer 23,290 129,226 7,371 
Merck 21,697 106,200 4,540 
Eli Lilly 9,584 40,500 2,144 
Johnson & Johnson  7,197 118,700 4,576 
Abbott 6,482 69,000 1,440 
Bristol-Myers Squibb  6,349 35,000 2,016 
Amgen  5,070 16,900 1,908 
Aggregate USA 78,194 515,526 23,995 
Note: Publications include those of subsidiaries, acquisitions and parent firms of mergers. Source: 
2009 UK R&D Scoreboard (BIS 2009)  
 
There is a lack of agreement among scholar about what R&D off-shoring to developing countries 
precisely entails (Ujjual et al. 2011). Due to the relatively distinct activities pursued in the stage of 
drug discovery (lab based) and drug development (clinically based) it may well be the case that R&D 
off-shoring takes place in some activities and not in others. Some scholars argue in this respect that 
there is a shift towards a globalisation of innovation, for example via externalisation of clinical trials 
to Contract Research Organisations (CROs) (Archibugi and Iammarino 1999), whereas others suggest 
that local R&D centres are concerned with adaptation to local markets, for example with research on 
disease prevalent in tropical areas or among certain population groups (von Zedtwitz and Gassmann 
2002). What do publications tell us? 
 
To our knowledge, this is the first large scale study of pharmaceutical publication trends. The only 
published previous studies are by Robert Tijssen, who showed trends of collaborative modes (Tijssen 
2004) or focused on the location of pharmaceutical R&D of European firms (Tijssen 2009). Our 
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analysis uses novel visualisation tools to intuitively convey to a non-ĞǆƉĞƌƚ ĂƵĚŝĞŶĐĞ ƚŚĞ ĨŝƌŵƐ͛ 
knowledge base (Rafols, Porter, and Leydesdorff 2010) and collaboration networks (Perianes-
Rodríguez, Olmeda-Gómez, and Moya-Anegón 2010). Data and bibliometric visualisations are made 
available in the Complementary Files listed in Appendix 1 and in a dedicated website.3  
 
Our results suggest a gradual decrease in internal big pharma research efforts and increasing 
reliance on external research. These empirical insights support the prevalent view that large 
pharmaceutical ĨŝƌŵƐ ĂƌĞ ŝŶĐƌĞĂƐŝŶŐůǇ ďĞĐŽŵŝŶŐ ͚ŶĞƚǁŽƌŬƐ ŝŶƚĞŐƌĂƚŽƌƐ͛ ƌĂƚŚĞƌ ƚŚĂŶ ƚŚĞ ƉƌŝŵĞ ůŽĐƵƐ 
of drug discovery (Hirschler and Kelland 2010, Hopkins et al. 2007). 
 
2. The limitations of using publication data to track ďŝŐ ƉŚĂƌŵĂ͛Ɛ R&D activity 
 
Publications cannot be assumed to be a reliable proxy to describe the dynamics of research in a 
private firm, even in a science-based area such as pharmaceuticals. For example, the concerns raised 
over the scientific integrity of research conducted by pharmaceutical companies are likely to have 
affected publication strategies, especially in the clinical fields (e.g. (Angell 2004; Smith 2005)). As 
well as a decline in R&D we also observe that pharmaceutical companies may face decreased 
legitimacy in science which may be reflected in their publishing patterns (Sismondo 2009). Careful 
analysis is thus needed to make inferences from publication data. 
  
TŽ ƵŶĚĞƌƐƚĂŶĚ ŚŽǁ ďŝŐ ƉŚĂƌŵĂ͛Ɛ ‘ΘD activity differs from its publication activity, it is helpful to 
consider the concept of Open Science. Open Science is based on the pursuit of priority, for example 
to claim credit for discovery and to hasten diffusion of knowledge, and as such encourages the rapid 
disclosure of research findings in scientific journals (Merton 1973; Stephan 1996). In contrast, firms 
often rely on secrecy and protective mechanisms such as patents to limit knowledge spillover risks 
and ensure returns to their investments(Dasgupta and David 1994). This implies that the 
contributions of big pharma to Open Science cannot be simply considered unconditional accounts of 
their research efforts and their scientific discoveries. Rather, scientific publication activity in firms is 
incentivized by commercial interests and by pressures imposed on them by prescribers, healthcare 
payers and regulators to disclose data.  
 
In the case of pharmaceutical research it is important to distinguish between the motivations firms 
have to publish during drug discovery and during drug development. With respect to the former, 
Hicks suggested ƚŚĂƚ ĨŝƌŵƐ ƉƵďůŝƐŚ ŝŶ ŽƌĚĞƌ ƚŽ ͚ƉĂƌƚŝĐŝƉĂƚĞ ŝŶ ƚŚĞ ďĂƌƚĞƌ-governed exchange of 
scientŝĨŝĐ ĂŶĚ ƚĞĐŚŶŝĐĂů ŬŶŽǁůĞĚŐĞ͛ ĂŶĚ ƚŽ ƐĞŶĚ ƐŝŐŶĂůƐ ƚŽ ŝŶǀĞƐƚŽƌƐ (Hicks 1995, 421). Adopting an 
Open Science strategy is in this case is considered necessary in order to connect to the scientific 
community and access its resources in the form of knowledge, qualified labour and informal advice 
(Hicks 1995; Cockburn and Henderson 1998). Investments in R&D are in this context a means to 
create absorptive capacity which is necessary both to take advantage of (upstream) research 
conducted outside the organizational boundaries of pharmaceutical firms. The advent of 
biotechnology has in this context been associated with an increased of explicit interaction between 
industry and academic science (McKelvey, Orsenigo, and Pammolli 2004). Firm strategies have thus 
ŵŽǀĞĚ ƚŽǁĂƌĚƐ Ă ŵŽƌĞ ŶĞƚǁŽƌŬĞĚ ĂŶĚ ͚ŽƉĞŶ͛ ŵŽĚĞů ŽĨ ŝŶŶŽǀĂƚŝŽŶ (Powell, Koput, and Smith-Doerr 
1996; Chesbrough 2003), in which publishing is seen as positively associated with innovative success 
(Jong and Slavcheva 2012). However whether open innovation leads to more open science is an 
open question.  
 
Concerning drug development, it can be argued that incentives to publish are higher than in other 
science-based industries, due to the highly regulated nature of drug development and the 
importance of clinical evidence for user uptake of innovations. Moreover, intellectual property will 
                                                          
3
 www.interdisciplinaryscience.net/pharma 
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already be in place on the underlying compound before drug development, which limits the risks of 
scooping. Scientific publications are therefore primarily written to diffuse information about the 
effectiveness and safety of pharmaceuticals to a wide range of stakeholders. This process is 
especially incentivized in an evidence-based medicine paradigm (Timmermans and Berg 2003; 
Montori and Guyatt 2008) which is an attempt to ground medical decisions directly in the available 
scientific evidence. It follows that pharmaceutical firms make use of publications as marketing tools 
that need to be carefully constructed and employed in order to win support in regulatory or policy 
arenas (e.g. in to gain approval of clinical trials) and in clinical settings (e.g. credibility among 
doctors) (Sismondo 2009; Smith 2005). In drug development scientific publications are also used as 
competitive devices to promote the superiority of a compound vis-a-vis potential substitutes 
introduced by competitors (Polidoro and Theeke 2011).  
 
While publications are therefore important in drug discovery and drug development, their analysis 
needs to be undertaken carefully because publications serve a variety of purposes. As a result, 
changes in publication trends can reflect different underlying phenomena. For example, the 
propensity to publish may change when a company shifts towards more science-based areas and 
wants to engage with academics (Hicks 1995). Similarly, in drug development, publication may 
underestimate research in pharmaceutical firms if industrial scientists publish their own research 
using ͚ŐŚŽƐƚ writers͛, i.e. hidden behind the alleged authorship of academics (Sismondo 2007). This 
occurs because of the higher credibility of academic ;ƉĞƌĐĞŝǀĞĚ ĂƐ ͚ĚŝƐŝŶƚĞƌĞƐƚĞĚ͛Ϳ ƌĞƐĞĂƌĐŚĞƌƐ͛ 
findings to investors and medical practitioners. Moreover, some portion of research may be 
expected to be held back from publication for reasons of commercial secrecy, as discussed above.  
 
A final consideration is the extent to which tracking the publications of the 15 largest firms in an 
industry tells us about the industry as a whole. There are thousands of firms now engaged in 
pharmaceutical R&D. Most of these are small, but some are quite large, being either old but 
comparatively small pharma, or young (compared to large pharma), non-traditional firms, for 
example biotechs such as Biogen. While the sample here do not represent the industry as a whole, 
the firms tracked in this sample account for over 50% of the pharmaceuticals brought to market 
since 1950 (based on (Munos 2009)) and hence represent the core of the traditional pharmaceutical 
industry. Furthermore because the publications tracked include those of firms acquired by big 
pharma over the studied period, the publications also incorporate the attempts by these firms to 
renew their capabilities. 
 
Given all these limitations, we conclude that the analysis of publications does not in itself reflect the 
ĚǇŶĂŵŝĐƐ ŽĨ ďŝŐ ƉŚĂƌŵĂ͛Ɛ ‘ΘD͘ HŽǁĞǀĞƌ͕ Ăƚ ƚŚĞ ŚŝŐŚ level of aggregation we conduct this study 
(based on about 10,000 publications per year in total, with around 150 to 1,500 publications per firm 
annually) it does raise interesting questions on R&D trends and firm strategies which then can be 
discussed a in comparison with complementary quantitative evidence to some trends revealed in 
other studies using a variety of other metrics such as patents and pharmaceutical projects (Kneller 
2010; Pammolli, Magazzini, and Riccaboni 2011). 
 
3. Materials and Methods 
 
The papers authored by staff at 15 major European and USA pharmaceutical firms were downloaded 
from Thomson-‘ĞƵƚĞƌ͛Ɛ Web of Science (WoS). Complementary File 1 (URL embedded) lists the firm 
names used in retrieval, including subsidiaries, mergers and acquisitions. Information on each 
ĐŽŵƉĂŶǇ͛Ɛ ĂĐƋƵŝƐŝƚŝŽŶƐ͕ ŵĞƌŐĞƌƐ ĂŶĚ ƐƵďƐŝĚŝĂƌŝĞƐ ǁĂƐ collected from their annual reports and the 
Recombinant capital database (http://www.recap.com/). TŚĞ ĚŽĐƵŵĞŶƚ ƚǇƉĞƐ ĐŚŽƐĞŶ ǁĞƌĞ ͞ĂƌƚŝĐůĞ͟, 
͞ůĞƚƚĞƌ͕͟ ͞ŶŽƚĞ͕͟ ͞ƉƌŽĐĞĞĚŝŶŐ ƉĂƉĞƌ͕͛ ĂŶĚ ͞ƌĞǀŝĞǁ͛ ĨŽƌ the period 1995-2009.  A total of 160,841 
records were obtained, standardised, processed and analysed with VantagePoint software 
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(http://thevantagepoint.com/). Publications were classified as European, when the affiliation 
contained at least one country in the European Union (EU) or in Switzerland, Norway, Lichtenstein 
and Iceland, the members of the European Free Trade Association (EFTA). The freeware programmes 
Pajek (http://pajek.imfm.si/) and VOSviewer (http://www.vosviewer.com/, (van Eck and Waltman 
2010)) were used for visualisation.  
 
To compare our dataset of the publications of the top 15 pharmaceutical firms to the field of 
sciences relevant to pharmaceutical R&D in general, we made two baseline datasets. First, to look 
into number of organisations and authors per paper, publications of the top 200 journals in which 
pharma published were downloaded from WoS. Two thousand publications were randomly selected 
from these journals for the years 1995, 1999, 2004 and 2009 and this data was used as a baseline for 
the Figure 5. Secondly, to investigate the relative change in the number of publications that list big 
pharma authors  per journal and field, the total number of publications for the period 1995-2009 of 
the top 350 Journals in which big pharma published were downloaded from the Journal Citations 
Reports. This data was used as a baseline for Table 2. 
 
4. Results: Shrinking knowledge production  
 
Big pharma has published about 11,000 publications per year in 1995-2009. This is a substantial 
contribution in the biomedical area, about 4% of all the publications (estimated from the 350 
journals where big pharma has the most publications). 
 
The first insight from this study is that big pharma firms have reduced the number of publications 
they produce by around 0.8% per annum when taking into account additional boosts to publication 
counts from subsidiaries and acquisitions prior to them joining their current parent. This amounts to 
a 9% decrease over 15 years, as shown in Figure 1. The results are a conservative estimate for the 
decrease, given that we are using full counting (i.e. without assigning fractions to co-authoring 
organisations) and collaborations are increasing over time (as discussed in section 4.2).  
 
This decrease is in stark contrast with R&D expenditure by large firms in the industry, which have 
increased in the order of 50% to 400% a decade (Arrowsmith 2012, 18) and the general inflationary 
tendency in publication volumes  revealed in bibliometric studies of global scientific output (Persson, 
Glänzel, and Danell 2004; Leydesdorff and Wagner 2009). In the areas where big pharma is 
publishing the most, we have estimated an annual growth rate of 1.1%, amounting to a 16% growth 
over the period (estimated from the 350 journals where big pharma has the most publications). As a 
result, publications by big pharma show a relative decrease, from 5% of the total in the specialised 
pharma fields in 1995 to 4% in 2009 (again estimated from 350 top pharma journals). This slow 
decline is consistent with other studies apparently showing an absolute decline of patenting in 
pharmaceutical US patent classes 424 and 514 (Subramanian, Toney, and Jayachandran 2011, 68) 
and relative decline of patenting by big pharma in comparison to small firms in biotechnology 
(Parimal Patel, Arundel, and Hopkins 2008, 51). 
 
However, if one looks at the publications by the core firms in our sample (defined as those with the 
name of the parent company or of mergers, see methods), one observes a modest increase of 0.6%, 
totalling an 8% growth over the period. The difference between growth in publications by core firms 
and a decrease in all big pharma publications can be attributed partly to R&D outsourcing, and partly 
to absorption and often rationalisation (i.e. closure) into the core firm of the R&D laboratories of the 
acquired firm. For example the former laboratories of firms such as Searle, Upjohn and Warner-
Lambert were closed some time after their acquisition by Pfizer (LaMattina 2011). Merck is 
estimated to have reduced its workforce by 30% after its merger with Schering-Plough in 2009 
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(McBride). All the pharmaceutical industry (not just big pharma) is estimated to have reduced its 
workforce by 300,000 people since 2000 (Herper 2011).  
 
 
Figure 1. Total number of publications per year of top 15 pharmaceutical firms.  
͚Core firms͛ includes only publications by R&D labs of the main firm or (or antecedĞŶƚ͛Ɛ ŶĂŵĞƐͿ 
before a merger. ͚Subsidiaries and Acquisitions͛ includes the outputs published under the name of 
the acquired firms before and after the transaction. 
 
Figure 2 illustrates the wider dynamics of apparent core firm enlargement with overall R&D 
shrinkage in the case of the GlaxoSmithKline, which saw a sharp decrease in its aggregate number of 
publications in the aftermath of the merger of Glaxo-Wellcome and SmithKline Beecham in 2000. In 
the cases of Pfizer, Novartis and Bayer, a similar dynamic is observed for acquisitions. The only firm 
that shows significant growth in publications over the period is Johnson & Johnson. Data for each 
firm is available at Complementary File 2.  
One can assume that the firms showing lower number of publications in relation to their R&D 
investment are also those with the highest degree of R&D outsourcing. For example,  Sanofi-Aventis, 
ǁŚŽ ŚĂƐ ƌĞĚƵĐĞĚ ŝƚƐ ƉƵďůŝĐĂƚŝŽŶƐ ƉĞƌ ǇĞĂƌ ĨƌŽŵ ΕϭϮϬϬ ƚŽ ΕϰϬϬ͕ ƌĞƉŽƌƚ ƚŚĂƚ ͚ŝŶ FĞď ϮϬϭϭ͕ ϲϰй ŽĨ ŽƵƌ 
development portfolio consisted of projects originated by external ‘ΘD͛  (Sanofi-Aventis 2010, 17).  
It appears that outsourcing is very actively pursued. AstraZĞŶĞĐĂ ƐƚĂƚĞƐ ƚŚĂƚ ͚WĞ ŝŶƚĞŶĚƐ ƚŽ ŝŶĐƌĞĂƐĞ 
our externalisation efforts to access the best, most cutting edge science, whatever its origin, with a 
target of 40% of our pipeline sources from outside our laboratories by 201ϰ͛ (AstraZeneca 2010, 29). 
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Figure 2. Number of publications per year of GlaxoSmithKline, its subsidiaries, and the parent 
firms before merger. See other firms in Complementary File 2. 
 
 
4.1 Cognitive shifts: Diversification of the knowledge base 
 
Next we examine the areas of research where large pharma is most active and how they changed 
over time. Figure 34 shows the distribution of the publications by big pharma over the global map of 
science (Rafols, Porter, and Leydesdorff 2010). Each node represents a research field as defined by 
Web of Science Categories. The position and colours of the nodes is given by their relative similarity 
(strong similarity is shown with links). The size (area) of nodes shows the percentage of publications 
in that area. Figure 3 illustrates that the knowledge base of pharmaceuticals is centred on 
biomedical sciences (green nodes: Pharmacology and Pharmacy, Biochemistry and Molecular 
Biology), with some important contributions in Chemistry (in blue: Organic Chemistry and Medicinal 
Chemistry), Immunology and Infectious Diseases, and then a few smaller areas of Clinical Medicine 
(in red). Data is available at Complementary File 3, for the aggregate and for each firm. 
 
Figure 4 shows the areas with positive (top) and negative (bottom) growth in publication numbers. 
The visualisation reveals a broad pattern of diversification, with a decrease in the traditional yet still 
dominant biomedical and chemical disciplines and an increase in peripheral areas related to new 
techniques (e.g. computational biology and related), and disciplines more oriented to clinical 
applications of therapeutics or health services.5 The latter observation is consistent with the 
ŽďƐĞƌǀĂƚŝŽŶ ƚŚĂƚ ͚ŝŶĚƵƐƚƌǇ ŚĂƐ ƐŚŝĨƚĞĚ ƌĞƐŽƵƌĐĞƐ ĂǁĂǇ ĨƌŽŵ ĚƌƵŐ ĚŝƐĐŽǀĞƌǇ ƚŽ ůĂƚĞ ĐůŝŶŝĐĂů 
ĚĞǀĞůŽƉŵĞŶƚƐ͛ (Munos and Chin 2011, 1). For example, the proportion of pharma-biotech alliances 
in the pre-clinical stage decreased from 46% to 38% in 2007-2011, while those in marketed stage 
increased from 24% to 28% of total (Ratner 2012, 119). 
 
                                                          
4
 For a webpage visualisation see http://www.scimago.es/perianes/spru/Interaction_Categories.html.  
5
 This diversification is captured by an increase in the Shannon-Wiener diversity (from 3.87 to 3.95). 
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In the cognitive sciences, one also observes a move away from basic science (e.g. Neuroscience) and 
towards more applied fields (Psychiatry and Clinical Neurology). The decrease in publications related 
to plants and environment is possibly due to the externalisation of the agrochemical divisions from 
pharmaceutical firms. For example, Syngenta was created in 2000 by the spinning out and merger of 
Zeneca Agrochemicals and Novartis Agribusiness. 
 
 
Figure 3. Distribution of publications by the top 15 pharmaceutical firms over the global map of 
science.  Nodes represent subject categories, with the area proportional to number of publications. 
The position of nodes is determined by similarity in citation patterns between the subject categories 
they represent.  
 
The growth of clinical areas such as oncology or rheumatology are consistent with data from 
pharmaceutical project data (Pammolli, Magazzini, and Riccaboni 2011, 431). However, for other 
areas, such as cardiovascular, research output in terms of publications is slowly increasing (2.5% 
over 10 years) in spite of a substantial (-5%) decrease in the number of projects  (Pammolli, 
Magazzini, and Riccaboni 2011). Such apparent inconsistencies, though not surprising given 
variations in field definition and unit of analysis, warn against hasty interpretations of data.  
 
Cognitive Sci.
Agri Sci
Biomed Sci
Chemistry
Physics
Engineering
Env Sci & Tech
Matls Sci
Infectious 
Diseases
Psychology
Social Studies
Clinical Med
Computer Sci.
Business & MGT
Geosciences
Ecol Sci
Econ. Polit. & Geography
Health & Social Issues
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Figure 4. Growth rate (top) and decrease rate (bottom) of publications by pharmaceutical firm in 
different scientific subject categories. Area of nodes is proportional to the growth (decrease) in 
publications. Only subject categories with more than 0.5% of the total publications are shown. 
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We also tried to visualise the specialisations of each firm using Web of Science publication data, but 
found big pharma had quite similar profiles at this coarse level of aggregation.6 In order to improve 
the granularity of description, we created a map based on the 191 journals that where big pharma 
publishes most frequently, available in Complementary File 4. See also interactive website: 
http://www.scimago.es/perianes/spru/Interaction_Companies.html. 
 
The results of the visualisation were mixed. These more granular maps (not shown in printed 
version) capture some of the specialisation patterns: for example, Eli LiůůǇ͛Ɛ ĨŽĐƵƐ ŽŶ ŵĞŶƚĂů ŝůůŶĞƐƐ͕ 
Žƌ NŽǀŽ NŽƌĚŝƐŬ͛Ɛ ĞĨĨŽƌƚ ŝŶ ĞŶĚŽĐƌŝŶŽůŽŐǇ͘ HŽǁĞǀĞƌ͕ ƚŚĞ ŵĂƉƐ ǁĞƌĞ ůĞƐƐ ƐƵĐĐĞƐƐĨƵů Ăƚ ĞůŝĐŝƚŝŶŐ ƚŚĞ 
differences in focus between larger firms such as Pfizer, Novartis or Merck. This may suggest 
isomorphic pressures in the industry as leading firms are joined by fast followers into new 
ƚŚĞƌĂƉĞƵƚŝĐ ĂƌĞĂƐ ;ƋƵŝƚĞ ůŝŬĞůǇ ŐŝǀĞŶ ƚŚĞ ŝŶĚƵƐƚƌǇ͛Ɛ ƌĞƉƵƚĂƚŝŽŶ ĨŽƌ ƉƌŽĚƵĐŝŶŐ ͚ŵĞ-ƚŽŽ͛ ĚƌƵŐƐ (Angell 
2004, 74ʹ93)), but we believe that this might also signal the need for new analyses requiring more 
sophisticated approaches, for example using keywords such as the Medical Subject Heading (MeSH) 
provided by PubMed (Leydesdorff, Rotolo, and Rafols 2012). 
 
TŚĞ ŽǀĞƌĂůů ƉŝĐƚƵƌĞ ŝƐ ƚŚĂƚ ďŝŐ ƉŚĂƌŵĂ͛Ɛ ŝƐ ƌĞĚƵĐŝŶŐ ƌĞƐĞĂƌĐŚ ŝŶ ĂƌĞĂƐ ŽĨ ƚƌĂĚŝƚŝŽŶĂů ĐŽƌĞ ĞǆƉĞƌƚŝƐĞ͕ 
namely in biomedical and chemistry areas, while at the same time diversifying into areas such as 
computational biology and fields that are closer to the patient (or perhaps market) such as health 
services and clinical research. However, as big pharma moves into new fields it relies more on 
external collaborations, as discussed in the next section.   
 
4.2 Organisational shifts: Increasing collaborations and out-sourcing 
 
The number of collaboration in science has been steadily increasing for decades  (Hicks and Katz 
1996; Wuchty, Jones, and Uzzi 2007). This trends towards ͚ƚĞĂŵ ƐĐŝĞŶĐĞ͛ ŚĂƐ ďĞĞŶ ƉĂƌƚŝĐƵůĂƌůǇ 
pronounced in the biological sciences, medicine and neuroscience (Porter and Rafols 2009, 730). Our 
data shows that such trends are even stronger in big pharma, but there is a twist: besides 
collaborating more, big pharma also allows their partners to take the lead in a greater proportion of 
publications produced from the collaborations. 
 
Figure 5 illustrates the increase of the number of authors and the number of organisations per 
article for pharmaceuticals in comparison with a sample of papers (baseline) in related fields (2,000 
publications per year of analysis randomly extracted from the 200 top journals of pharma 
publication). Not only are pharmaceutical papers more collaborative, but their co-authorships are 
growing faster than average in the fields in which they publish.  
 
A crucial observation from studying co-authorship is that in big pharma collaborations, the external 
partners increasingly play the leading intellectual role. This is shown in Table 2, by the significant 
decrease in the percentage of big pharma-based first authors in collaborative publications (from 43% 
to 35%), and of big pharma-based corresponding authors (from 41% to 34%) over the period studied.   
 
This trend is more prominent in the fields and journals into which big pharma has more recently 
entered (arguably those where new competences are more likely to be demanded), in contrast to 
the fields and journals where big pharma is shrinking its publication output (which are those of 
traditional core expertise). In the fields with increasing output, the share of big pharma 
corresponding authors decreased from 44%- to 36% in 1998-2009 (and from 47% to 39% in the ten 
fastest growing). In the case of areas with declining output, the share of ƉŚĂƌŵĂ͛Ɛ ĐŽƌƌĞƐƉŽŶĚŝŶŐ 
authorship remained quite stable, declining only from 52% to 49% (from 52% to 48% in those 
                                                          
6
 A previous study had shown no effect of these small field differences between firms on innovation 
performance  ;D͛EƐƚĞ ϮϬϬϱ͕ ϯϳͿ. 
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declining fastest). Likewise, the percentage of corresponding authors in growing journals decreased 
from 52% to 47% (from 70% to 60% in ten fastest growing), whereas the percentage in shrinking 
journals only declined marginally from 51% to 49% (from 51.2% to 50.5% in ten fastest shrinking). 
The inertia in the maintenance of the core expertise and the difficulty in catching up with new fields, 
is a general characteristic of firm dynamics given the cumulative nature of firms technological 
competences (Hopkins et al. 2007; P. Patel and Pavitt 1997). 
 
 
 
Figure 5. Trends in collaborative practices in pharma R&D publications, compared to control 
publications in the same scientific fields (baseline). 
 
The overall picture is consistent with a trend towards R&D outsourcing, driven by pressures to seek 
cost efficiencies (Baum, 2010).  Outsourcing entails a reduction of internal R&D laboratory capacity 
and the parallel expansion of alliance networks with small firms and academic laboratories (Powell, 
Koput, and Smith-Doerr 1996), in which big pharma is intellectual follower rather than the leader. 
This does not necessarily imply ƚŚĂƚ ďŝŐ ƉŚĂƌŵĂ͛Ɛ ĂďŝůŝƚǇ ƚŽ ĐĂƉƚƵƌĞ ǀĂůƵĞ ĨƌŽŵ ƚŚĞƐĞ ĂůůŝĂŶĐĞƐ ŝƐ 
reduced and this may be a topic for further study.  
 
Table 2. Trends in scientific leadership in co-authored publications  
Year  1998
(1)
 2002 2006 2009 
% publications with external collaboration 62.1% 67.6% 69.1% 71.7% 
% organisations collab. baseline (estimate) 55.0% 59.0% 63.2% 66.4% 
      
Pharma-based first author  43.1% 38.4% 36.2% 35.0% 
      
Pharma-based corresponding author 40.7% 36.6% 35.0% 33.6% 
 In expanding fields2) 43.9% 38.9% 35.9% 35.6% 
 In shrinking fields(2) 52.3% 50.1% 50.5% 48.8% 
     
Pharma corresp. author (top 350 journals) 50.8% 46.5% 47.3% 47.0% 
 In expanding journals 52.4% 48.0% 48.1% 46.6% 
 In shrinking journals 50.9% 46.4% 47.6% 48.8% 
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Notes: (1) Data starts in 1998 due to partial missing data on corresponding and first authors in 1995-1997. (2) 
Since some journals are assigned to various fields (Web of Science Categories), this figure is a slight 
overestimate.  
 
4.2 Geographical shifts 
 
4.3.1 The decline of ďŝŐ ƉŚĂƌŵĂ͛Ɛ European R&D  
 
It has been suggested that European pharmaceuticals firms have weakened over recent decades 
(McKelvey, Orsenigo, and Pammolli 2004). The trends confirm such decline both in terms of the 
publications of all European R&D laboratories (shown in Figure 6, left, including labs of American 
ĨŝƌŵƐ͕ ƐƵĐŚ ĂƐ PĨŝǌĞƌ͛Ɛ ƐŝƚĞ Ă “ĂŶĚǁŝĐŚ͕ UKͿ͕ ĂŶĚ ŽĨ Ăůů ůĂďŽƌĂƚŽƌŝĞƐ ŽĨ ĨŝƌŵƐ ǁŝƚŚ EƵƌŽƉĞĂŶ 
headquarters (shown in Figure 6, right, including USA labs of European firms). Besides the decline in 
number of publications, European-headquartered firms have also decreased the proportion of 
publications that they lead, as shown by number of corresponding authors, from 45% to 35% (Figure 
6, right), whereas US-based firms have undergone a less marked decline (from 52% to 47%). 
Geographical data discussed in this section is available in Complementary File 5. 
Figure 7 shows that the decline of ďŝŐ ƉŚĂƌŵĂ͛Ɛ European publications has been concentrated in the 
UK, Switzerland and France. In contrast, big pharma have maintained their German publication 
output and increased their output in smaller European countries such as Sweden, Belgium and 
Denmark.  
 
Part of the European decline may be attributed to the fact that whereas Europe-based firms have 
located an important share of their R&D activities in USA laboratories (producing about 35%), USA-
based firms on the other hand have a smaller presence in Europe (producing only 22% of their 
publications). This is illustrated in Figure 8 (left).  
 
Such imbalances in the USA versus European presence of big pharma has been previously well 
documented, e.g. by publications (Tijssen 2009) and patent inventors (Friedman 2010; Pammolli, 
Magazzini, and Riccaboni 2011). In the latter case, patent concentration in the home continent of 
the firm is even more acute, as shown in Table 3. These data should be taken as conservatives 
estimates of home country because publication data counts the publications of acquired firms with 
the parent company ʹwhich means that acquisitions explain a very important proportion of the non-
home publicatiŽŶƐ ŽĨ ĨŝƌŵƐ͘ FŽƌ ĞǆĂŵƉůĞ͕ ‘ŽĐŚĞ͛Ɛ ůĂƌŐĞ ƉĞƌĐĞŶƚĂŐĞ ŽĨ U“A ƉƵďůŝĐĂƚŝŽŶƐ ŝƐ ƉĂƌƚůǇ 
ĞǆƉůĂŝŶĞĚ ďǇ ŝƚƐ ĂĐƋƵŝƐŝƚŝŽŶ ŽĨ GĞŶĞŶƚĞĐŚ͖ Žƌ JŽŚŶƐŽŶ ĂŶĚ JŽŚŶƐŽŶ͛Ɛ ůĂƌŐĞ EƵƌŽƉĞĂŶ ƉƌĞƐĞŶĐĞ ŝƐ 
largely due to its Belgian subsidiary Janssen.  
 
 
 
Figure 6. Publications by location of pharmaceutical R&D laboratories (left). Publications by 
locations of firm headquarters (right), for all publications (top) and for those with big pharma 
affiliations for the corresponding author (bottom).  
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Figure 7. Location of pharmaceutical R&D laboratories authoring papers 
 
 
 
 
Figure 8. Location of pharmaceutical R&D laboratories (left) and external collaborators (right) on 
headquarters base (Europe vs. US).  
 
Although in most of this analysis we adopt a Europe versus USA perspective, a more careful analysis 
of the data reveals that European pharmaceutical companies are still remarkably national (or bi-
national as a results of mergers in the case of AstraZeneca and Sanofi-Aventis) (see Table 3). Outside 
their home countries, European firms have more publications from US-based labs than all their non-
ĚŽŵĞƐƚŝĐ EƵƌŽƉĞĂŶ ůĂďƐ ;ŝ͘Ğ͘ EƵƌŽƉĞ ĞǆĐůƵĚŝŶŐ ƚŚĞ ͚ŚŽŵĞ ĐŽƵŶƚƌǇ͛ ŽĨ ƚŚĞ ĨŝƌŵͿ͘ Such is the extent of 
the national base for collaborations that when co-authorships are mapped into organisational 
networks there are striking similarities to the natural geographic distribution of countries, as shown 
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in Figure 9, with big pharma playing a notable role spanning the bibliometric equivalent of the 
͚AtůĂŶƚŝĐ͛.7  
 
One recurrent argument of why European (or Japanese) pharmaceutical firms locate R&D centres in 
the US is that American basic biomedical research is of higher quality than European research (e.g. 
see (McKelvey, Orsenigo, and Pammolli 2004) ʹ indeed there is a parallel discussion on this in 
relation to other industries (Dosi, Llerena, and Labini 2006). Given this argument, it seems 
paradoxical that although USA-based firms have much less R&D in Europe than their EU-based 
counterparts, both USA and European-based firms have a very similar percentage of their total 
publications with external collaborators from across the Atlantic (about 40%). Given that the vast 
majority of these external collaborators are public research organisations, one can argue that in 
pharmaceutical research European public research is probably not so bad after all.  Alternatively it 
may reflect that the strategic interest of USA-based firms in the European pharmaceutical market is 
equal to the interest of European-based firms in the USA pharmaceutical market, as local 
collaborations are needed to prepare drugs launches in those markets. Given this interest, scientific 
activities may well be employed across the Atlantic for marketing reasons, patient availability and 
proximity to regulators and medical practitioner. The rapid increase in clinical trial activities in 
Central and Eastern European countries may also be a reason for this.   
 
Table 3. CŽŵƉĂƌŝƐŽŶ ďĞƚǁĞĞŶ ͚HŽŵĞ ĐŽƵŶƚƌǇ͛ ĂŶĚ ƌĞŐŝŽŶĂů ůŽĐĂƚŝon of research in 1995-2009.  
 
  % of Publications % 
Patents
(2)
 
Company Home  
Country 
Home  
Country 
Europe
(1) 
USA Rest of  
World 
 by US 
inventors 
USA Firms    
Pfizer USA See USA 24.2 75.6 3.4 81 
Merck USA See USA 24.3 71.0 8.3 88 
Eli Lilly USA See USA 19.9 81.7 3.9 n.a. 
Johnson & Johnson  USA See USA 33.9 65.7 4.7 86 
Abbott USA See USA 22.7 77.0 1.8 90 
Bristol-Myers Squibb  USA See USA 7.2 93.0 2.0 90 
Amgen  USA See USA 3.2 94.4 3.8 n.a. 
Aggregate USA   76.8 22.0 76.8 4.8  
European Firms    
GlaxoSmithKline  UK 44.5 15.8 43.9 2.4 47 
Novartis Switzerland 41.1 21.6 40.2 4.4 26 
Hoffmann–La Roche Switzerland 24.4 17.6 50.8 10.7 46 
AstraZeneca  UK & Sweden 77.7 3.7 19.4 3.4 19 
Sanofi-Aventis  Fran. & Germ.(3) 63.5 11.5 23.9 5.3 20 
Bayer Germany 62.2 6.8 29.2 5.7 n.a. 
Novo Nordisk  Denmark 87.5 4.3 9.1 2.3 n.a. 
Boehringer Ingelheim  Germany 40.8 17.2 34.9 14.7 n.a. 
Aggregate EU
(4)   51.5 14.0 35.7 5.4 n.a. 
Aggregate EU     63.3 35.7 5.4 n.a. 
Notes: (1) IŶ ƚŚŝƐ ƚĂďůĞ͕ ͚Europe͛ excludes the home country in the case of European firms. (2) Source: 
Pammolli et al. (2011, p.434). Based on location of ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĨŝƌŵƐ͛ inventors on patents from 1980-2004. 
                                                          
7
 See interactive map at http://www.scimago.es/perianes/spru/Interaction_Colaborations.html 
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(3) The headquarters of Sanofi-Aventis are in France, but during the period under study one of its antecedent 
companies, Hoechst, had its headquarters in Germany. (4) This European aggregate is based on the sum of 
European firms. It includes double counting (estimated at 2.5%) due to collaboration between firms.  
 
 
 
Figure 9. Collaboration network of pharmaceutical firms.  
 
4.3.2 Limited globalisation ʹ so far. 
 
If there is a decline of European R&D associated with off-shoring and outsourcing of R&D, is there 
evidence of an increase in publications of R&D in emerging countries associated with this? The 
answer, for now, is negative. The percentage of big pharma publications outside of USA and Europe 
has remained stably low, increasing only from about 500 to about 650 publications per year over the 
period 1995-2009, although in relative terms these publications have increased from 4% to 6% of big 
ƉŚĂƌŵĂ͛Ɛ total. Most of these publications (~60-70%) have originated in advanced economies such 
as Japan and Canada. Following investments in R&D centres (Anon. 2010) countries such as 
Singapore, India and China show rapid growth in publications starting from a very low base. 
However, the absolute number of publications emerging from big pharma͛Ɛ new eastern R&D 
laboratories is still very low, and with only the exception of Singapore less than 20 publications/year 
on average as shown in Figure 10 (compared with ~200 in Italy or ~600 in Switzerland).8  
 
Emerging countries are a comparatively much more important contributor of publications from 
external pharma collaborations. Whereas in 1998, only 10% of big pharma collaborators were from 
outside of Europe or the USA, this figure increased to 15% by 2009. This growth is partly due to the 
                                                          
8
 The numbers are so low that one wonders if research carried out in R&D laboratories in emerging countries is 
published with affiliations of the headquarter laboratories. Such practice has been observed in patents. 
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growing importance of universities in developed economies such as Canada and Australia (35% and 
17% of ͚ƌĞƐƚ ŽĨ ƚŚĞ ǁŽƌůĚ͛ ĐŽůůĂďŽƌĂƚŝǀĞ publications in 2009, respectively). However, part of the 
increase was also due to rapid increase in the collaborations between big pharma and public 
research organisations in countries such as China (157 publications in 2009), Brazil (98), South Korea 
(75), India (57) and Singapore (55). These collaborations are mainly between local public research 
organisations and R&D labs of big pharma in other countries. As shown in Table 4, co-location of 
local research organisations and local big pharma R&D labs does not appear to be the driver behind 
the increase of ďŝŐ ƉŚĂƌŵĂ͛Ɛ collaborative publications by emerging countries. 
 
A more plausible explanation for the increasing collaboration of pharma with emerging economies is 
the rapid globalization of clinical research activities (Thiers, Sinskey, and Berndt 2008; Petryna 2009). 
The conduct of clinical trials requires the involvement of many individuals which often necessitates a 
division of labour between those researchers that are appointed in the scientific management teams 
that design the study and analyze the data, and (clinical) investigators that merely enrol patients for 
data analysis. It is the latter͛Ɛ activity that is increasingly conducted in emerging economies and in 
this case relations between pharmaceutical companies and researchers from these countries are 
often mediated by a third party such as a Contract Research Organizations (CROs). The increase in 
external collaborators in emerging economies may be a reflection of this and it is likely that the 
observed scientific activities of these countries is in this case an underestimation as authorship for 
publication mainly accrues to researchers with scientific leadership and less often to the researchers 
that are actually engaged with patients on the ground in this type of clinical work (Hoekman et al. 
2012). 
 
In summary, publication data raises questions about the extent to which the opening of R&D centres 
in emerging economies such as India or China constitute a globalisation of pharmaceutical R&D ʹin 
ƚŚĞ ƐĞŶƐĞ ŽĨ ŵĂŬŝŶŐ ƚŚĞƐĞ ŶĞǁ ĐĞŶƚƌĞƐ ͚ĐŽŵƉĞƚŝƚŽƌƐ͛ ƚŽ ƚŚŽƐĞ ŝŶ ƚŚĞ ĚĞǀĞůŽƉĞĚ ĐŽƵŶƚƌŝĞƐ͘ The small 
number of publications from big pharma labs in these countries is consistent with relatively small 
units of 70 to 300 researchers in most cases (Ujjual et al. 2011), but also suggests these R&D labs are 
so far fulfilling other purposes, in particular an adaptation of their products to the emerging markets. 
These include: (i) research on issues specific to human and physical geographies such as tropical 
diseases or genetic susceptibilities; (ii) development of low cost drugs to cater for the medical needs 
in terms of cost and dosage of developing country populations; (iii) establishment of links with CROs 
conduction clinical trials, as well as broadening the genetic make-up of clinical trial populations (iv) 
presence in large markets with growing wealth and its associated medical needs, e.g. diabetes, 
cardiovascular complications (Anon. 2010; Ujjual et al. 2011, 22).  
 
Since the globalisation of pharmaceutical R&D centres is a recent phenomenon and publication 
takes times, there is the possibility that publication counts do not capture the most up-to-date 
trends. Singapore, the emerging country with most publications, saw the investment in new pharma 
labs (Lilly, Novartis, Pfizer) in the early 2000s, whereas most centres in China have only opened since 
the mid 2000s (Roche in 2004; Pfizer and Sanofi-Aventis in 2005; GSK and AstraZeneca in 2007; 
Novartis, 2008; Lilly and Johnson and Johnson in 2009; source: (Anon. 2010)).  
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Figure 10. Location of pharmaceutical R&D laboratories by emergent countries. 
 
 
Table 4. Collaborations between local research organisations and local R&D labs of big pharma in 
emerging countries.  
 
Country of External Collaboration 
% in collaboration with  
ďŝŐ ƉŚĂƌŵĂ͛Ɛ ůŽĐĂů ‘ΘD ůĂďƐ  
1995-99 2000-04 2005-09 
India 19% 36% 26% 
Singapore 11% 18% 19% 
China 6% 4% 13% 
South Korea 4% 13% 13% 
Brazil 17% 9% 13% 
South Africa 15% 9% 4% 
 
 
5. Discussion: CĂƵƐĞƐ ĂŶĚ ĐŽŶƐĞƋƵĞŶĐĞƐ ŽĨ ƉŚĂƌŵĂ͛Ɛ ƌĞƚƌĞĂƚ ĨƌŽŵ ŽƉĞŶ ƐĐŝĞŶĐĞ 
 
This paper has analysed the publication output of the 15 major pharmaceutical firms in Europe and 
the US, including publications by all acquisitions made by these firms in the period 1995-2009,  that 
represents the core of the traditional pharmaceutical industry ʹ big pharma. The analysis suggests 
that these firms are undergoing a shift away from the open science activities associated with drug 
discovery and towards a systems integrator role (Munos 2009; Paul et al. 2010; Pammolli, Magazzini, 
and Riccaboni 2011; Hopkins et al. 2007). 
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Our empirical data provides some evidence of this shift from three perspectives. In the first place, a 
diversification of the knowledge base away from the tradition expertise in chemistry and biology 
towards computation, health services and more clinical fields.  This diversification may be 
characterised crudely as a shift from basic towards clinical research, from research to development, 
or from bench towards bedside. Such a shift might be resulting from technological opportunities 
created by information technologies (Nightingale 2000; Bonaccorsi 2008), as the outcome of socio-
economic ƉƌĞƐƐƵƌĞƐ ŝŶ ŵĞĚŝĐŝŶĞ ƚŽǁĂƌĚƐ ƉƌĂĐƚŝĐĞƐ ƚŚĂƚ ĂƌĞ ŵŽƌĞ ƐĞŶƐŝƚŝǀĞ ƚŽ ƚŚĞ ƉĂƚŝĞŶƚ͛Ɛ ĐŽŶƚĞǆƚ or 
individual needs (Amir-Aslani and Mangematin 2010) and/or of management strategies to reduce 
the financial risk associated with drug discovery (Munos and Chin 2011)9. 
 
Second, to access these new areas of knowledge we observe an increase in external collaborations 
and of external leadership of co-authored papers, suggesting a tendency to outsource, in agreement 
with industry reports of increasing externalisation of R&D efforts (Baum 2010; Hirschler and Kelland 
2010). Such trends are consistent with the view that the locus of innovation is shifting from in-house 
R&D to small firms and public organisations (Munos 2009; Kneller 2010) or to the organisational 
network (Powell, Koput, and Smith-Doerr 1996). However these expanding collaborations are 
increasingly intellectually led by the collaborators rather than big pharma. Whether this has any 
ŝŵƉůŝĐĂƚŝŽŶƐ ĨŽƌ ďŝŐ ƉŚĂƌŵĂ͛Ɛ ability to capture values from these relationships remains to be 
explored.  
 
Third, from the geographic perspective, we find a more pronounced decline in publications by 
Europe-based ďŝŐ ƉŚĂƌŵĂ ;ŝŶĐůƵĚŝŶŐ ƚŚĞŝƌ U“ ůĂďƐͿ ĂƐ ǁĞůů ĂƐ ƚŽƚĂů ŽƵƚƉƵƚ ŽĨ ďŝŐ ƉŚĂƌŵĂ͛Ɛ EƵƌŽƉĞĂŶ 
labs (including those owned by US firms), in comparison to all big pharma labs located in the US or 
all labs owned by USA firms. The relative decline in European laboratories is not uniform, with 
Germany resisting the trend, while the UK, France and Switzerland succumb most, and Sweden, 
Denmark and Belgium buck the trend entirely. The shift away from undertaking internal R&D in 
Europe does not detract from the importance of European collaborators for big pharma ʹ with 
European collaborators apparently as important to US-based big pharma as US collaborators are to 
EU-based big pharma.  
 
Finally, wŚŝůĞ ƉƵďůŝĐĂƚŝŽŶƐ ďǇ ͚big pharma͛ ŝŶ ĞŵĞƌŐĞŶƚ ĐŽƵŶƚƌŝĞƐ have sharply increased, from a low 
base, over the period studied, these remain extremely low compared with those in developed 
countries. Publishing activity in these R&D centres in developing countries have so far a small 
͚ƌĞƐĞĂƌĐŚ͛ ĐŽŵƉŽŶĞŶƚ ĂŶĚ Ă ůĂƌŐĞƌ ͚ĚĞǀĞůŽƉŵĞŶƚ͛ ĐŽŵƉŽŶĞŶƚ͕ ƉŽƐƐŝďůǇ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ adaptation 
to local growing markets and coordination of the research outsourcing to local CROs or public 
centres (Hoekman et al. 2012). 
 
Finally, we observe a slow decline of the total number of publications by big pharma, in stark 
contrast with the inflationary tendencies of most bibliometric indicators in the period (Persson, 
Glänzel, and Danell 2004). This confirms earlier suggestions of a publication decline from corporate 
laboratories, inferred from a shorter period (1996-2001) and only for certain collaborative modes 
(Tijssen 2004).  Based on our empirical data we can merely argue that there seems to be a shift away 
from an ͚ŽƉĞŶ ƐĐŝĞŶĐĞ͛ ƐƚƌĂƚĞŐǇ in pharma, which might be due to either a decrease of R&D 
performed in-house by  pharma (possibly due to increased R&D outsourcing), or a decrease in the 
propensity to publish. As carefully argued by Tijssen (Tijssen 2004, 726ʹ727), one cannot rule out the 
possibility that big pharma is conducting the same or greater amount of R&D, but just publishing less 
ʹfor example, because academic collaborators refrain from mentioning industrial involvement or 
because of fears of knowledge leaking out before patenting. Or it could be also be that the retreat 
from publishing activities is due to a combination of increasing costs in the business of medical 
                                                          
9
 See (Pammolli, Magazzini, and Riccaboni 2011) for an oppositve view on risk taking. 
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writing, heightened ĂǁĂƌĞŶĞƐƐ ďǇ ŵĞĚŝĐĂů ũŽƵƌŶĂůƐ ŽĨ ƚŚĞ ͚ŵĂƌŬĞƚŝŶŐ͛ ĨƵŶĐƚŝŽŶ ŽĨ ƉŚĂƌŵĂ ĂƌƚŝĐůĞƐ 
and/or in the wake of scandals following ethically dubious practices such ghost writing (Sismondo 
2009; Smith 2005). 
 
However, industry analysts report of R&D laboratories closures (LaMattina 2011), decrease of R&D 
expenditure in comparison to sales (from the traditional 15-20% to ~10% according to (Petsko 2011, 
3)), outsourcing of R&D (Hirschler and Kelland 2010; Baum 2010), relative reduction of research in 
comparison to development (Jensen 2010) and a drop by half in number of new pharma-biotech 
alliances (Ratner 2012). This strongly suggests ƚŚĂƚ ƉŚĂƌŵĂ͛Ɛ ŝŶ-house R&D efforts are decreasing 
significantly. In fact, the decline in publication trends shown in Figure 1 might be a gross 
underestimate of the degree of in-house R&D reduction, because of increasing co-authorship trends 
observed during the period.   
 
In any case, either of these (perhaps complementary) interpretations tells of a decline in the 
importance of open science consistent with the idea that pharmaceutical companies are increasingly 
͚ŶĞƚǁŽƌŬ ŝŶƚĞŐƌĂƚŽƌƐ͛  instead of the prime locus of drug discovery (Subramanian, Toney, and 
Jayachandran 2011). As the chief executive of GlaxoSmithKline explains: 
 
͚Big Pharma players can no longer hope to generate the absolutely best science in all areas 
on their own. Therefore, rebuilding the R&D Engine in Big Pharma standard operating 
procedure should be to decide on a scientific bet (for example, kinases in oncology), shop 
around among all the external players that are pursuing such research, and establish a 
contractual relationship with the best.͛ (Garnier 2008, 75ʹ76) 
 
In doing so, they are following other high-tech sectors, such as various firms in semiconductors and 
information technologies in the retreat from corporate R&D (Tijssen 2004; The Economist 2007). 
Instead of being the R&D engine, big pharma, as network integrator, is possibly taking on the role of 
financier, regulatory liaison, and lobbyists for publicly funded medical research, and salesman. 
Whether this is a desirable development depends on the belief in the capacities of big pharma to 
coordinate and integrate these activities for the public good. 
 
At this stage, one can only speculate on the causes and consequences of big pharma͛Ɛ retreat from 
open science. In a linear view on innovation where high-quality scientific activity results in new 
compounds, big pharma͛Ɛ lack of investment in in-house science (or at least in genuine high risk 
research) can be seen as the cause of its R&D productivity crisis (Munos and Chin 2011). Another 
view is that R&D cuts are just the consequence of the crisis: higher R&D costs and expiring patents 
lead to lack of investment which results in a shortage of capital to keep R&D.10  
 
Any discussion of the causality chains in ďŝŐ ƉŚĂƌŵĂ͛Ɛ ĂƉƉĂƌĞŶƚ structural transition will be complex 
and is beyond the scope of this study. An understanding of the industry evolution would require an 
analysis not only of corporate R&D activities, but of its interplay of financial markets, emerging 
economies, increased regulatory stringency, demography changes resulting in new types of disease 
addressed, technologies used in drug discovery, and changes in health provision triggered by welfare 
cuts. We nevertheless speculatively advance two debates where the retreat of big pharma from 
open science will figure centrally. 
 
The first debate is about the ďŝŐ ƉŚĂƌŵĂ͛Ɛ capabilities of carrying out the role system integrator 
while reducing its role as contributor to the scientific base. If science-based knowledge is becoming 
more important in drug discovery, and firms need to develop absorptive capacity by interacting with 
academia and small biotechs in order to acquire this knowledge (Cockburn and Henderson 1998), 
                                                          
10
 We thank Ed Steinmueller for this point. 
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how will they be able to select which areas to invest in the absence of a substantial in-house 
ƌĞƐĞĂƌĐŚ͍ TŚĞ ĂƉƉĂƌĞŶƚ ĂŶƐǁĞƌ ĂƉƉĞĂƌƐ ƚŽ ďĞ ĨŽƌ ĂĐĂĚĞŵŝĂ ƚŽ ƐƚĞƉ ŝŶ ďǇ ĚŽŝŶŐ ͚ƚƌĂŶƐůĂƚŝŽŶĂů 
ƌĞƐĞĂƌĐŚ͛ and setting up private-public cĞŶƚƌĞƐ ƚŚĂƚ ĨĂĐŝůŝƚĂƚĞ ͚ŽƉĞŶ ŝŶŶŽǀĂƚŝŽŶ͛ (Collins 2011; West 
and Nightingale 2009). The viability of this model is unproven. 
 
The second debate concerns how the redistribution of research efforts will or should affect the 
redistribution of the social benefits and economic returns derived from drugs. Some observers have 
seriously questioned the economic returns enjoyed by big pharma in the last 20 years (Angell 2004; 
Mazzucato 2011, 96), in particular given the crucial contributions already made by public research 
(McMillan, Narin, and Deeds 2000) and the forthcoming increases (Collins 2011). ‘ĞƵƚĞƌƐ͛ ĂŶĂůǇƐƚƐ 
have put it eloquently (Hirschler and Kelland 2010, 9): 
 
͚Drug companies have long promoted the idea that they pursue new drugs for the good of 
humanity; it's an argument Big Pharma regularly uses to justify the huge profits it makes. 
High returns, the industry argues, can be ploughed back into research on the next medical 
breakthrough. If Big Pharma is not doing the research itself, will the big margins be harder to 
defend?͛ 
 
In summary, the analysis of publications over the last 15 years has provided us with a window on an 
apparently major transition in the pharmaceutical industry. Multidimensional studies weaving trends 
in the knowledge base results with financial, regulatory and social trends will be needed to better 
understand and steer future scenarios of health provision (Crommelin et al, 2009).  
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